ArticleInternational journal of nanomedicine2017
Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment.
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- Nanoparticles in gynecologic cancers: a bibliometric and visualization analysis.Frontiers in oncology · 2024Pooled it
- Cubosome-Based Nanocarriers in Cancer Therapy: Design Optimization, Analytical Characterization, and Translational Perspectives.Annals of biomedical engineering · 2026Review
- Green Synthesis of Bioactive Silver Nanoparticles fromPharmaceutics · 2025Article
- Applications of Nanoparticles in the Diagnosis and Treatment of Ovarian Cancer.Nanomaterials (Basel, Switzerland) · 2025Review
- Biosynthesis of silver nanoparticles from plant extracts: a comprehensive review focused on anticancer therapy.Frontiers in pharmacology · 2025Review
- Influence of silver nanoparticles' size on their direct interactions with doxorubicin and its biological effects.Scientific reports · 2024Article
- Silver nanoparticles induces apoptosis of cancer stem cells in head and neck cancer.Toxicology reports · 2024Article
- Efficient ultrasound-mediated drug delivery to orthotopic liver tumors - Direct comparison of doxorubicin-loaded nanobubbles and microbubbles.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Biomedical Approach of Nanotechnology and Biological Risks: A Mini-Review.International journal of molecular sciences · 2023Review
- Efficient ultrasound-mediated drug delivery to orthotopic liver tumors - Direct comparison of doxorubicin-loaded nanobubbles and microbubbles.bioRxiv : the preprint server for biology · 2023Article
- Article
- Nano-biotechnology in tumour and cancerous disease: A perspective review.Journal of cellular and molecular medicine · 2023Review
- Review
- In Vivo Efficacy of Wound Healing under External (Bio)AgNCs Treatment: Localization Case Study in Liver and Blood Tissue.International journal of molecular sciences · 2022Article
- Synthesis of Silver Nanocomposite Based on Carboxymethyl Cellulose: Antibacterial, Antifungal and Anticancer Activities.Polymers · 2022Article
- AgPharmaceuticals (Basel, Switzerland) · 2022Review
- Light-emitting diode (LED)-directed green synthesis of silver nanoparticles and evaluation of their multifaceted clinical and biological activities.RSC advances · 2022Article
- Development, Therapeutic Evaluation and Theranostic Applications of Cubosomes on Cancers: An Updated Review.Pharmaceutics · 2022Review
- Green Silver Nanoparticles Promote Inflammation Shutdown in Human Leukemic Monocytes.Materials (Basel, Switzerland) · 2022Article
- A Review on Plants and Microorganisms Mediated Synthesis of Silver Nanoparticles, Role of Plants Metabolites and Applications.International journal of environmental research and public health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGemcitabine (GEM) is widely used as an anticancer agent in several types of solid tumors. Silver nanoparticles (AgNPs) possess unique cytotoxic features and can induce apoptosis in a variety of cancer cells. In this study, we investigated whether the combination of GEM and AgNPs can exert synergistic cytotoxic effects in the human ovarian cancer cell line A2780.
methodsWe synthesized AgNPs using resveratrol as a reducing and stabilizing agent. The synthesized nanomaterials were characterized using various analytical techniques. The anticancer effects of a combined treatment with GEM and AgNPs were evaluated using a series of cellular assays. The expression of pro- and antiapoptotic genes was measured using real-time reverse transcription polymerase chain reaction. Apoptosis was confirmed by TUNEL assay.
resultsIn this study, combined treatment with GEM and AgNPs significantly inhibited viability and proliferation in A2780 cells. Moreover, the levels of apoptosis in cells treated with a combination of GEM and AgNPs were significantly higher compared with those in cells treated with GEM or AgNPs alone. Our data suggest that GEM and AgNPs exhibit potent apoptotic activity in human ovarian cancer cells. Combined treatment with GEM and AgNPs showed a significantly higher cytotoxic effect in ovarian cancer cells compared with that induced by either of these agents alone.
conclusionOur study demonstrated that the interaction between GEM and AgNPs was cytotoxic in ovarian cancer cells. Combined treatment with GEM and AgNPs caused increased cytotoxicity and apoptosis in A2780 cells. This treatment may have therapeutic potential as targeted therapy for the treatment of ovarian cancer. To our knowledge, this study could provide evidence that AgNPs can enhance responsiveness to GEM in ovarian cancer cells and that AgNPs can potentially be used as chemosensitizing agents in ovarian cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.